Baxter International Inc (BAX) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals.

Total Revenue Chart for Baxter International Inc

Baxter International Inc (BAX) revenue for FY2025 was USD 11.2B, a 5.7% change from FY2024. Baxter International Inc's revenue grew from USD 2.4B in 1985 to USD 11.2B in 2025 (377.5% over 40 years). Earnings per share grew from USD 1.25 in 2000 to USD -1.87 in 2025 (-249.6%). Revenue compound annual growth rate: 5-year CAGR of -0.7%, 10-year CAGR of 1.2%, 20-year CAGR of 0.7%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$14.13B
Implied Share Price
$27.33
Enterprise Value
$21.04B
Revenue (TTM)
$11.47B
EBITDA
$1.88B
Profit Margin
-9.27%
Trailing P/E
—
Forward P/E
13.77
Price/Book (MRQ)
2.18
Price/Sales (TTM)
1.22
EV/EBITDA
27.61
EV/Revenue
1.83
Dividend Yield
0.71%
Book Value
$12.00
Free Cash Flow (FY2025)
$323.00M
Free Cash Flow Yield
2.29%

Snapshot as of 6th August 2026 — not point-in-time controlled, may lag the live market by a few days.